This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Ogsiveo (nirogacestat)
General Description:
Ogsiveo (nirogacestat) is an oral prescription medication indicated for adult patients with progressing desmoid tumors who require systemic treatment. It works by inhibiting gamma-secretase, a key enzyme involved in tumor growth, helping to slow disease progression and improve patient outcomes.
Ogsiveo is administered orally as tablets, with dosage and treatment schedules determined by a qualified healthcare professional based on individual patient needs.
Getting Ogsiveo (nirogacestat) in India
Ogsiveo has been approved in the USA since November 2023. While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE assists Indian patients in obtaining Ogsiveo safely, managing all regulatory approvals, import permits, and logistics for a secure and compliant process.
Disease Indication:
• Soft Tissue Sarcoma / Progressing Desmoid Tumors
Manufacturer:
Springworks
Usage:
Oral Tablets
Medicine Approved By:
• Food and Drug Administration (FDA)
Available Dosage Form & Package:
• 100 mg tablets, 14 tablets per pack
• 150 mg tablets, 14 tablets per pack
Shipping:
Room Temperature Shipping
Ogsiveo is shipped under controlled room temperature conditions (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Ogsiveo (nirogacestat) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Ogsiveo (nirogacestat) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
